https://www.selleckchem.com/pr....oducts/nf-kb-activat
Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking. To investigate the effectiveness of dupilumab in patients with atopicdermatitis (AD) in the Netherlands and Japan over 80weeks of treatment. A longitudinal comparative cohort study was conducted in patients with AD who were treated with dupilumab in daily practice. We used linear mixed-effects models to determine changes over time. We found statistically significant differences in sex, disease on
Like
Comment
Share
